Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
Trial details
- Registry ID
- NCT02143648
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as nalbuphine ER
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic PruritusNCT02143648 | Trevi Therapeutics | Phase 2, Phase 3 | Completed | 2015-07Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |